DAFNA Capital Management’s Immunomedics Inc IMMU Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-260,905
| Closed | -$22.2M | – | 90 |
|
|
2020
Q3 | $22.2M | Buy |
260,905
+10,000
| +4% | +$506K | 7.21% | 2 |
|
|
2020
Q2 | $8.89M | Buy |
+250,905
| New | +$7.34M | 2.57% | 8 |
|
|
2019
Q2 | – | Sell |
-5,052
| Closed | -$97K | – | 93 |
|
|
2019
Q1 | $97K | Sell |
5,052
-77,202
| -94% | -$1.24M | 0.04% | 78 |
|
|
2018
Q4 | $1.17M | Sell |
82,254
-95,746
| -54% | -$1.9M | 0.58% | 46 |
|
|
2018
Q3 | $3.71M | Sell |
178,000
-5,000
| -3% | -$118K | 1.52% | 22 |
|
|
2018
Q2 | $4.33M | Sell |
183,000
-97,900
| -35% | -$1.97M | 2.03% | 15 |
|
|
2018
Q1 | $4.1M | Sell |
280,900
-23,100
| -8% | -$377K | 2% | 18 |
|
|
2017
Q4 | $4.91M | Sell |
304,000
-156,451
| -34% | -$1.85M | 2.65% | 11 |
|
|
2017
Q3 | $6.44M | Sell |
460,451
-177,249
| -28% | -$1.77M | 4% | 4 |
|
|
2017
Q2 | $5.63M | Buy |
637,700
+385,126
| +152% | +$2.7M | 4.02% | 3 |
|
|
2017
Q1 | $1.63M | Sell |
252,574
-307,100
| -55% | -$1.56M | 1.38% | 25 |
|
|
2016
Q4 | $2.05M | Sell |
559,674
-7,122
| -1% | -$21.1K | 1.8% | 20 |
|
|
2016
Q3 | $1.84M | Sell |
566,796
-248,204
| -30% | -$694K | 1.28% | 26 |
|
|
2016
Q2 | $1.89M | Buy |
+815,000
| New | +$2.72M | 1.5% | 19 |
|
DAFNA Capital Management's IMMU Position: Q4 2020 in Review
DAFNA Capital Management sold out of Immunomedics Inc (IMMU) in Q4 2020, closing a stake of 260,905 shares — an estimated $22.2M sold.
DAFNA Capital Management first reported a position in IMMU in Q2 2016 and held it in 14 quarters. The position peaked at $22.2M in Q3 2020. 0 funds tracked by Wall St. Rank hold IMMU as of Q4 2020.
- DAFNA Capital Management reported no remaining Immunomedics Inc position as of Q4 2020 after selling out during the quarter.
- DAFNA Capital Management sold 260,905 Immunomedics Inc shares in Q4 2020, an estimated $22.2M.
- DAFNA Capital Management first reported a position in Immunomedics Inc in Q2 2016 and held it in 14 quarters.
- DAFNA Capital Management's Immunomedics Inc position peaked at $22.2M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2020.
Based on DAFNA Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.